… Targeted therapy has emerged as an … cell lung cancer (NSCLC). Herein, we review and
analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer…

… This design of clinical trials of testing the efficacy of targeted therapies … targeted therapy
trials in lung cancer with other actionable oncogenic drivers. Molecular profiling of lung cancers …

… the selective pressure exerted by each targeted therapy. In some (but not all) cases, the
evolution of TKI resistance can lead to significant tumor heterogeneity within a given cancer. …

… of individualized therapy. In this article we review clinical data for molecular-targeted
therapies in NSCLC, with emphasis on EGF-R, VEGF-R and other novel targets. Nonetheless, for …

… Since 1998, when trastuzumab was the first molecularly targeted drug approved by US …
cancers until the end of 2009. However, the clinical response obtained from targeted therapies is …

… Perhaps the best example of how biomarker-driven targeted therapy has shifted the paradigm
of lung cancer treatment is the management of EGFR-mutant NSCLC. Activating mutations …

… effective targeted therapies in metastatic NSCLC. Currently, five molecular targeted agents
… This review will focus on the rationale for the development of targeted therapies in NSCLC …

… Non-small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
… Here, we review the development of targeted therapies for the treatment of advanced or …

… shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be …
without a known driver mutation, targeted therapy is pushing the boundary to significantly …

… effect of targeted therapy on lung cancer outcomes has been … the limitations of targeted
therapy in lung cancer and, indeed… aberration of CML, lung cancer cells are characterized by …